People · Operator
Named in public records as an officer, director or promoter · active 2008–2018 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Grail, Inc. | — | Biotechnology | Growth/Late | $2.2B | $2.9B | 2017 |
| Sage Therapeutics, Inc. | — | Pharmaceuticals | Growth/Late | $698.0M | $20.7B | 2014 |
| Fate Therapeutics Inc | — | Biotechnology | Series C | $241.3M | $2.0B | 2009 |
| Ikaria Holdings Inc | — | Pharmaceuticals | Series C | $54.9M | $1.9B | 2008 |
| NeurogesX Inc | — | Pharmaceuticals | Series B | $26.3M | $23.3M | 2011 |
Robert T. Nelsen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert T. Nelsen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 2 | 22 |
| Bryan E. Roberts | 2 | 6 |
| William Rastetter | 2 | 4 |
| William T. Rastetter | 2 | 2 |
| Bryan Roberts | 1 | 18 |
| Michael Lee | 1 | 15 |
| Amir Nashat | 1 | 14 |
| Carl Weissman | 1 | 8 |
| Robert Epstein | 1 | 8 |
| Richard Klausner | 1 | 7 |
| PAUL Grayson | 1 | 5 |
| MIN CUI | 1 | 5 |
| DAVID E. SHAW | 1 | 5 |
| Lota S Zoth | 1 | 4 |
| John Mendlein | 1 | 4 |
| ROBERT S. EPSTEIN | 1 | 3 |
| AMIR S. NASHAT | 1 | 3 |
| Michael F. Cola | 1 | 3 |
| Catherine Friedman | 1 | 3 |
| Hans Bishop | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.